Summary
Fifty patients with advanced (stage III or IV) ovarian carcinoma were followed-up until the date of their death or their fifth year of survival. Prognostic factors, including those currently in use, as well as ploidy and proliferation, chemoresistance testing and hormone receptor levels of the tumours were analysed for predictive value and independence from each other. In the univariate analysis, only stage, residual tumour, second-look status, chemoresistance, ploidy and proliferation were significantly correlated with survival. After being tested in a multivariate Cox regression model, however, only the results of chemoresistance testing at initiation of therapy, and second-look status at a later point, retained prognostic significance. Within the group of patients with a positive second-look, i.e., with the worst prognosis, the chemoresistance test was still able to discriminate between two subgroups with significantly different survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abel U, Berger J, Wiebelt H (1985) Critlevel: an exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inform Med 23:154–156
FIGO (1988) Annual Report of Treatment in Gynecological Cancer, Vol. 20. International Federation of Gynecology and Obstetrics, Stockholm
Edler L, Wahrendrof J, Berger J (1980) Survival — a program package for the statistical analysis of censored survival times. Statistical Software Newslett 6:44–53
Group for Sensitivity Teting of Tumors (KSST) (1981) In-vitro short-term-test to determine the resistance of human tumors to chemotherapy. Cancer 48:2127–2135
Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van der Velde EA, Nooy M (1988) The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis. Gynecol Oncol 30:347–358
Heintz APM, Van Oosterom AT, Trimbos JBMC, Schaberg A, Van der Velde E, Nooy M (1988) The treatment of advanced ovarian carcinoma (II): interval reassessment operations during chemotherapy. Gynecol Oncol 3:359–371
Kallioniemi O, Hietanen T, Mattila J, Lahtinen M, Lauslahti K, Koivula I (1987) Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Onc 23:277–282
Kallioniemi OP, Mattila J, Punnonen R, Koivula T (1988) DNA ploidy level and cell cycle distribution in ovarian cancer relation to histopathological features of the tumor. Int J Gynecol Pathol 7:7–11
Khoo SK, Hurst T, Lark J, Webb MJ, Parson P, Mackay EV (1989) In vitro sensitivity of ovarian cancer as determined by a short-term biomedical assay: comparison between primary and metastatic sites in the same patient. Gynecol Oncol 32:151–155
Khoo SK, Hurst T, Weeb MJ, Dickie G, Kearsley J, Parson PG, Mackay EV (1989) Clinical value of in vitro drug sensitivity testing based on short-term effects on DNA and RNA metabolism in ovarian cancer. J Surg Oncol 41:201–205
Korenmann SG, Dukes BA (1970) Specific estrogen binding by the cytoplasm of human breast carcinomas. J Clin Endocrinol Metab 30:639–645
Mangioni C, Bonazzi C, Colombo N, Epis A, Landoni F, Vassena L, Mangili G, Torri W (1989) Pathologic complete responses in advanced epithelial ovarian cancer: prognostic factors for long-term survival. In: Conte PF (ed) Multimodal treatment of ovarian cancer. Raven Press, New York
Mattern J, Volm M (1982) Clinical relevance of predictive tests for cancer chemotherapy. Cancer Treatment Reviews 9:267–298
Schwartz PE (1985) Steroid hormone-receptors and antiestrogen therapy in ovarian neoplasms. In: Roth L, Czernobilski B (eds) Tumors and tumorlike conditions of the ovary. Churchill Livingstone, New York, p 233–246
Sevelda P, Dittrich CH, Salzer H (1989) The value of second-look operation in patients with advanced ovarian carcinoma. Arch Gynecol Obstet 244:79–86
Volm M, Wayss K, Kaufmann M, Mattern J (1979) Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer 15:983–993
Volm M, Brüggemann A, Günther M, Kleine W, Pfleiderer A, Vogt-Schaden M (1985) Prognostic relevance of ploidy, proliferation, and resistance-predictive tests in ovarian carcinoma. Cancer Res 45:5180–5185
Volm M, Mattern J, Sonka J, Vogt-Schaden M, Wayss K (1985) DNA distribution in non-small cell lung carcinomas and its relationship to clinical behavior. Cytometry 6:345–356
Volm M, Drings P, Mattern J, Sonka J, Vogt-Moykopf I, Wayss K (1985) Prognostic significance of DNA patterns and resistance-predictive tests in non-small cell lung carcinoma. Cancer 56:1396–1403
Volm M, Kleine W (1987) Prognostische Bedeutung von durchflußzytophotometrischen Untersuchungen beim Ovarialkarzinom. Geburtsh Frauenheilkd 47:456–459
Volm M, Mattern J, Müller T, Drings P (1988) Flow cytometry of epidermoid lung carcinomas: relationship of ploidy and cell cycle phases to survival. A five-year follow up study. Anticancer Res 8:105–112
Volm M, Drings P, Hahn EW, Mattern J (1988) Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in-vitro short term test. Br J Cance 57:198–200
Volm M, Kleine W, Pfleiderer A (1989) Flow-cytometric prognostic factors for the survival of patients with ovarian carcinoma. A five-year follow up study. Gynecol Oncol 35:84–89
Author information
Authors and Affiliations
Additional information
Recipient of a grant from the Spanish Social Security Investigation Fund (FISS)
Rights and permissions
About this article
Cite this article
Schneider, J., Edler, L., Kleine, W. et al. DNA analysis, chemoresistance testing and hormone receptor levels as prognostic factors in advanced ovarian carcinoma. Arch Gynecol Obstet 248, 45–52 (1990). https://doi.org/10.1007/BF02389589
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02389589